Coya Therapeutics (COYA) Cash from Financing Activities (2022 - 2026)

Coya Therapeutics (COYA) has 5 years of Cash from Financing Activities data on file, last reported at $11.0 million in Q1 2026.

• For the quarter ending Q1 2026, Cash from Financing Activities rose 57356.17% year-over-year to $11.0 million; the trailing twelve-month figure through Mar 2026 stood at $31.4 million (up 111.85% YoY), and the FY2025 full-year result was $20.4 million, up 27.21% from the prior year.
• Cash from Financing Activities retreated to $11.0 million in Q1 2026, from $20.3 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $24.2 million in Q4 2023 to a low of -$104071.0 in Q4 2022.
• A 5-year average of $6.8 million and a median of $3.2 million in 2024 frame the typical range for Cash from Financing Activities.
• Across the five-year window, Cash from Financing Activities tumbled 98.46% in 2025 and jumped 57356.17% in 2026, its largest moves.
• Tracing COYA's Cash from Financing Activities over 5 years: stood at -$104071.0 in 2022, then surged by 23329.1% to $24.2 million in 2023, then plunged by 59.91% to $9.7 million in 2024, then soared by 109.95% to $20.3 million in 2025, then sank by 45.97% to $11.0 million in 2026.
• Business Quant data shows COYA's Cash from Financing Activities at $11.0 million in Q1 2026, $20.3 million in Q4 2025, and $19137.0 in Q3 2025.